MDH1 Recombinant Monoclonal Antibody

Malate dehydrogenase 1 (MDH1) serves as a critical enzyme in cellular metabolism, catalyzing the reversible oxidation of malate to oxaloacetate in the cytoplasm. As a key component of the malate-aspartate shuttle, MDH1 facilitates the transfer of reducing equivalents across the mitochondrial membrane, playing an essential role in maintaining cellular redox balance and energy homeostasis. Its involvement in metabolic reprogramming has made it an increasingly important target in cancer metabolism and signal transduction research.

This recombinant monoclonal antibody, developed using rabbit host immunization against a synthetic peptide derived from human MDH1, offers the reproducibility and consistency that demanding experimental workflows require. The sequence-defined nature of recombinant production ensures that each lot performs identically to the last, eliminating the variability that can compromise longitudinal studies or multi-site collaborations.

Validation studies demonstrate robust performance across multiple applications. Western blot analysis confirms specific detection of MDH1 at the expected 36 kDa molecular weight across a diverse panel of human cell lines including Jurkat, HepG2, U251, HEK293, and PC-3 cells. Cross-species reactivity extends to mouse NIH/3T3 cells and rat heart tissue, providing flexibility for researchers working across model systems. Immunohistochemical staining in paraffin-embedded human prostate cancer tissue reveals clear target localization, while flow cytometry analysis in A431 cells demonstrates suitability for single-cell applications with distinct population separation from isotype controls.

Whether investigating metabolic enzyme expression patterns, exploring MDH1's role in tumor metabolism, or characterizing signal transduction pathways, this antibody delivers the specificity and versatility needed for rigorous experimental design.